Annual Drug Patent Expirations for TRADJENTA
Tradjenta is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from two suppliers. There are ten patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for TRADJENTA.
This drug has three hundred and ninety-one patent family members in forty-five countries.
The generic ingredient in TRADJENTA is linagliptin. Two suppliers are listed for this compound. Additional details are available on the linagliptin profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
